69 results
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in multiple diseases, and have focused our resources … and alternative complement pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye, and clinical … pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
of complement inhibition defines active treatment window Rapid C1q engagement and functional inhibition (CH50 assay) § 30 mg/kg provided: ~1 week duration … ANX005 has demonstrated rapid target engagement in blood & CSF across multiple central and peripheral neurological disorders A single dose of ANX005
8-K
EX-99.1
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Strength, Nerve Damage and Ventilation
ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses
Real-World Evidence
424B5
wtkr b5ievqbu964w2f
5 Apr 24
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
5mvetkl9i cq
4 Mar 24
Regulation FD Disclosure
5:25pm
424B5
tc43w mia1m
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
hhbiz4t4yz2dno2uzxj2
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
njvvf h1g
25 May 23
Other Events
6:08am
8-K
EX-99.1
h1wtwdi
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am